uniQure (NASDAQ:QURE) Given Overweight Rating at Cantor Fitzgerald

uniQure (NASDAQ:QURE)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a research report issued on Friday, Benzinga reports. They currently have a $28.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 410.02% from the stock’s previous close.

Several other research analysts have also weighed in on QURE. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of uniQure in a research note on Tuesday, August 20th. The Goldman Sachs Group upped their price target on shares of uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, uniQure has a consensus rating of “Hold” and an average price target of $19.40.

uniQure Stock Down 3.2 %

Shares of uniQure stock traded down $0.18 during trading on Friday, reaching $5.49. The stock had a trading volume of 196,666 shares, compared to its average volume of 1,526,666. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $267.36 million, a price-to-earnings ratio of -0.88 and a beta of 0.95. uniQure has a 52 week low of $3.73 and a 52 week high of $11.35. The stock has a fifty day moving average price of $6.83 and a two-hundred day moving average price of $5.63.

uniQure (NASDAQ:QURE) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.08. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%. The business had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $3.47 million. Sell-side analysts predict that uniQure will post -4.04 EPS for the current fiscal year.

Hedge Funds Weigh In On uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. lifted its stake in shares of uniQure by 58.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock worth $52,000 after buying an additional 3,664 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares during the last quarter. Total Clarity Wealth Management Inc. bought a new stake in shares of uniQure during the second quarter worth approximately $74,000. SG Americas Securities LLC bought a new position in shares of uniQure during the second quarter worth approximately $79,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in uniQure by 130.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 14,454 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.